Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of$55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of$113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Akebia T ...